{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:28:08Z","timestamp":1787495288831,"version":"build-2736575974"},"reference-count":75,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.cpet.2026.02.003","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:11:53Z","timestamp":1775560313000},"page":"403-413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Novel Theranostic Targets for Prostate Cancer Beyond Prostate-Specific Membrane Antigen"],"prefix":"10.1016","volume":"21","author":[{"given":"Pedram","family":"Heidari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Jadvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar","family":"Kako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadi A.","family":"Esfahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cpet.2026.02.003_bib2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00259-024-06857-w","article-title":"Standardized template for clinical reporting of PSMA PET\/CT scans","volume":"52","author":"Esfahani","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.cpet.2026.02.003_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40644-024-00658-y","article-title":"Advances of radiolabeled GRPR ligands for PET\/CT imaging of cancers","volume":"24","author":"Ma","year":"2024","journal-title":"Cancer Imaging"},{"issue":"11","key":"10.1016\/j.cpet.2026.02.003_bib4","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.2967\/jnumed.121.263159","article-title":"PSMA expression assessed by PET imaging is a required biomarker for selecting patients for any PSMA-targeted therapy","volume":"62","author":"Calais","year":"2021","journal-title":"J Nucl Med"},{"issue":"23","key":"10.1016\/j.cpet.2026.02.003_bib5","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The role of lineage plasticity in prostate cancer therapy resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.cpet.2026.02.003_bib6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2967\/jnumed.124.268861","article-title":"Gastrin-releasing peptide receptor imaging and therapy in the era of personalized medicine","volume":"66","author":"Morgat","year":"2025","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2026.02.003_bib7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.7150\/thno.13580","article-title":"In vivo stabilization of a gastrin-releasing peptide receptor antagonist enhances PET imaging and radionuclide therapy of prostate cancer in preclinical studies","volume":"6","author":"Chatalic","year":"2016","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.cpet.2026.02.003_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/biom13071134","article-title":"Preclinical characterization of a stabilized gastrin-releasing peptide receptor antagonist for targeted cancer theranostics","volume":"13","author":"Abouzayed","year":"2023","journal-title":"Biomolecules"},{"issue":"5","key":"10.1016\/j.cpet.2026.02.003_bib9","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2967\/jnumed.117.197624","article-title":"Prospective evaluation of 68Ga-RM2 PET\/MRI in patients with biochemical recurrence of prostate cancer and negative findings on conventional imaging","volume":"59","author":"Minamimoto","year":"2018","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.cpet.2026.02.003_bib10","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2967\/jnumed.122.263971","article-title":"Correlation of 68Ga-RM2 PET with postsurgery histopathology findings in patients with newly diagnosed intermediate- or high-risk prostate cancer","volume":"63","author":"Duan","year":"2022","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.cpet.2026.02.003_bib11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(24)00069-X","article-title":"68Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2\/3 imaging trial","volume":"25","author":"Duan","year":"2024","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.cpet.2026.02.003_bib12","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2967\/jnumed.120.259630","article-title":"PSMA- and GRPR-targeted PET: results from 50 patients with biochemically recurrent prostate cancer","volume":"62","author":"Baratto","year":"2021","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2026.02.003_bib13","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3390\/cancers14020334","article-title":"68Ga-PSMA and 68Ga-DOTA-RM2 PET\/MRI in recurrent prostate cancer: diagnostic performance and association with clinical and histopathological data","volume":"14","author":"Mapelli","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.cpet.2026.02.003_bib14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00259-019-04504-3","article-title":"First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer","volume":"47","author":"Kurth","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.cpet.2026.02.003_bib15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2967\/jnumed.116.176636","article-title":"68Ga\/177Lu-NeoBOMB1, a novel radiolabeled GRPR antagonist for theranostic use in oncology","volume":"58","author":"Dalm","year":"2017","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1016\/j.cpet.2026.02.003_bib16","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.2967\/jnumed.120.258814","article-title":"GRPr antagonist 68Ga-SB3 PET\/CT imaging of primary prostate cancer in therapy-na\u00efve patients","volume":"62","author":"Bakker","year":"2021","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2026.02.003_bib17","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s11307-018-1185-z","article-title":"In vivo stabilized SB3, an attractive GRPR antagonist, for pre- and intra-operative imaging for prostate cancer","volume":"20","author":"Bakker","year":"2018","journal-title":"Mol Imaging Biol"},{"issue":"6","key":"10.1016\/j.cpet.2026.02.003_bib18","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2967\/jnumed.123.267017","article-title":"Prospective comparison of 68Ga-NeoB and 68Ga-PSMA-R2 PET\/MRI in patients with biochemically recurrent prostate cancer","volume":"65","author":"Duan","year":"2024","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1016\/j.cpet.2026.02.003_bib19","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3390\/pharmaceutics16111358","article-title":"Theranostic potential of the iPSMA-bombesin radioligand in patients with metastatic prostate cancer: a pilot study","volume":"16","author":"Gonz\u00e1lez-Rueda","year":"2024","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.cpet.2026.02.003_bib20","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"13","key":"10.1016\/j.cpet.2026.02.003_bib21","first-page":"4792","article-title":"Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer","volume":"9","author":"Ayala","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.cpet.2026.02.003_bib22","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.cpet.2026.02.003_bib23","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3389\/fimmu.2019.01835","article-title":"The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment","volume":"10","author":"Monteran","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.cpet.2026.02.003_bib24","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.pathol.2024.12.637","article-title":"Overexpression of fibroblast activation protein (FAP) in the stroma of proliferative inflammatory atrophy (PIA) and primary adenocarcinoma of the prostate","volume":"57","author":"Caramella-Pereira","year":"2025","journal-title":"Pathology"},{"issue":"3","key":"10.1016\/j.cpet.2026.02.003_bib25","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.118.215913","article-title":"68Ga-FAPI PET\/CT: Biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers","volume":"60","author":"Giesel","year":"2019","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.cpet.2026.02.003_bib26","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","article-title":"Development of fibroblast activation protein-targeted radiotracers with improved tumor retention","volume":"60","author":"Loktev","year":"2019","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2026.02.003_bib27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2967\/jnumed.120.245084","article-title":"FAPI-74 PET\/CT using either 18F-AlF or cold-kit 68Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients","volume":"62","author":"Giesel","year":"2021","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.cpet.2026.02.003_bib28","first-page":"1952","article-title":"FAP and PSMA expression by immunohistochemistry and PET imaging in castration-resistant prostate cancer: a translational pilot study","volume":"65","author":"Huang","year":"2024","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2026.02.003_bib29","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1053\/j.semnuclmed.2025.06.010","article-title":"[177Lu]Lu-FAPI radioligand therapy: emerging horizons and clinical promise in solid tumors: a comprehensive review","volume":"55","author":"Al-Ibraheem","year":"2025","journal-title":"Semin Nucl Med"},{"issue":"19","key":"10.1016\/j.cpet.2026.02.003_bib30","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1158\/1078-0432.CCR-22-1432","article-title":"Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities","volume":"28","author":"Fendler","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.cpet.2026.02.003_bib31","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using 177Lu-FAP-2286: first-in-humans results","volume":"63","author":"Baum","year":"2022","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.cpet.2026.02.003_bib32","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1021\/cbmi.3c00067","article-title":"225Ac-labeled antibody for fibroblast activation protein-targeted alpha therapy","volume":"1","author":"Song","year":"2023","journal-title":"Chem Biomed Imaging"},{"issue":"4","key":"10.1016\/j.cpet.2026.02.003_bib33","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1073\/pnas.95.4.1735","article-title":"Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer","volume":"95","author":"Reiter","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.cpet.2026.02.003_bib34","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/01.ju.0000109982.60619.93","article-title":"Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer","volume":"171","author":"Han","year":"2004","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.cpet.2026.02.003_bib35","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/sj.onc.1203426","article-title":"Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer","volume":"19","author":"Gu","year":"2000","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.cpet.2026.02.003_bib36","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2967\/jnumed.113.120873","article-title":"Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody","volume":"55","author":"Knowles","year":"2014","journal-title":"J Nucl Med"},{"issue":"21","key":"10.1016\/j.cpet.2026.02.003_bib37","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.7150\/thno.27679","article-title":"Dual-modality ImmunoPET\/fluorescence imaging of prostate cancer with an anti-PSCA cys-minibody","volume":"8","author":"Tsai","year":"2018","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.cpet.2026.02.003_bib38","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","article-title":"PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"30","author":"Dorff","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.cpet.2026.02.003_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-53220-6","article-title":"PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial","volume":"15","author":"Stein","year":"2024","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.cpet.2026.02.003_bib40","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1158\/1078-0432.CCR-20-3310","article-title":"Molecular imaging of prostate cancer targeting CD46 using ImmunoPET","volume":"27","author":"Wang","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.cpet.2026.02.003_bib41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13046-023-02636-x","article-title":"CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment","volume":"42","author":"Li","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.cpet.2026.02.003_bib42","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1158\/1078-0432.CCR-22-3291","article-title":"Treatment of prostate cancer with CD46-targeted 225Ac alpha particle radioimmunotherapy","volume":"29","author":"Bidkar","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.cpet.2026.02.003_bib43","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.7150\/thno.92742","article-title":"Development of CD46 targeted alpha theranostics in prostate cancer using 134Ce\/225Ac-Macropa-PEG4-YS5","volume":"14","author":"Bobba","year":"2024","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.cpet.2026.02.003_bib44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-019-0745-2","article-title":"DLL3: an emerging target in small cell lung cancer","volume":"12","author":"Owen","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.cpet.2026.02.003_bib45","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2967\/jnumed.121.263221","article-title":"Molecular imaging of neuroendocrine prostate cancer by targeting delta-like ligand 3","volume":"63","author":"Korsen","year":"2022","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1016\/j.cpet.2026.02.003_bib46","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S1470-2045(24)00249-3","article-title":"Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1\/2, first-in-human trial","volume":"25","author":"Tendler","year":"2024","journal-title":"Lancet Oncol"},{"issue":"27","key":"10.1016\/j.cpet.2026.02.003_bib47","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2203820119","article-title":"Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer","volume":"119","author":"Korsen","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.cpet.2026.02.003_bib48","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study","volume":"18","author":"Rudin","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2026.02.003_bib49","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/path.6063","article-title":"Oncofetal protein glypican-3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer","volume":"260","author":"Butler","year":"2023","journal-title":"J Pathol"},{"issue":"10","key":"10.1016\/j.cpet.2026.02.003_bib50","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1172\/JCI128212","article-title":"Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer","volume":"129","author":"Labrecque","year":"2019","journal-title":"J Clin Investig"},{"issue":"5","key":"10.1016\/j.cpet.2026.02.003_bib51","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.devcel.2008.03.006","article-title":"Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding","volume":"14","author":"Capurro","year":"2008","journal-title":"Dev Cell"},{"issue":"supplement 2","key":"10.1016\/j.cpet.2026.02.003_bib52","first-page":"241022","article-title":"Novel GPC3-targeted radiopharmaceutical therapy for hepatocellular carcinoma and prostate cancer: preclinical characterization in rodents and non-human primates","volume":"65","author":"Lin","year":"2024","journal-title":"J Nucl Med"},{"issue":"14","key":"10.1016\/j.cpet.2026.02.003_bib53","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","article-title":"Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.cpet.2026.02.003_bib54","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.trecan.2018.03.010","article-title":"B7-H3 in cancer - beyond immune regulation","volume":"4","author":"Flem-Karlsen","year":"2018","journal-title":"Trends Cancer"},{"issue":"3","key":"10.1016\/j.cpet.2026.02.003_bib55","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.eururo.2022.09.004","article-title":"B7-H3 as a therapeutic target in advanced prostate cancer","volume":"83","author":"Guo","year":"2023","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.cpet.2026.02.003_bib56","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/pcan.2016.49","article-title":"Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis","volume":"20","author":"Benzon","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.cpet.2026.02.003_bib57","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186388","article-title":"A whole-body imaging technique for tumor-specific diagnostics and screening of B7H3-targeted therapies","volume":"135","author":"Xia","year":"2025","journal-title":"J Clin Investig"},{"issue":"25","key":"10.1016\/j.cpet.2026.02.003_bib58","doi-asserted-by":"crossref","first-page":"14523","DOI":"10.1073\/pnas.96.25.14523","article-title":"STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors","volume":"96","author":"Hubert","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"10.1016\/j.cpet.2026.02.003_bib59","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.2967\/jnumed.118.222844","article-title":"Imaging patients with metastatic castration-resistant prostate cancer using 89Zr-DFO-MSTP2109A anti-STEAP1 antibody","volume":"60","author":"Carrasquillo","year":"2019","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.cpet.2026.02.003_bib60","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.2967\/jnumed.114.145185","article-title":"Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET","volume":"55","author":"Doran","year":"2014","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2026.02.003_bib61","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","article-title":"Xaluritamig, a STEAP1 \u00d7 CD3 XmAb 2+1 immune therapy for metastatic castration-resistant prostate cancer: results from dose exploration in a first-in-human study","volume":"14","author":"Kelly","year":"2024","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.cpet.2026.02.003_bib62","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1089\/ten.tea.2008.0519","article-title":"Six-transmembrane epithelial antigen of the prostate (STEAP1 and STEAP2)-differentially expressed by murine and human mesenchymal stem cells","volume":"15","author":"Vaghjiani","year":"2009","journal-title":"Tissue Eng Part A"},{"issue":"1","key":"10.1016\/j.cpet.2026.02.003_bib63","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41698-024-00599-6","article-title":"Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: expression landscape and molecular correlates","volume":"8","author":"Ajkunic","year":"2024","journal-title":"npj Precis Oncol"},{"issue":"16","key":"10.1016\/j.cpet.2026.02.003_bib64","doi-asserted-by":"crossref","first-page":"14318","DOI":"10.18632\/oncotarget.3960","article-title":"Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts","volume":"6","author":"Trerotola","year":"2015","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.cpet.2026.02.003_bib65","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s00259-013-2434-7","article-title":"Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody","volume":"40","author":"van Rij","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.cpet.2026.02.003_bib66","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s44276-024-00106-1","article-title":"Efficacy and safety of sacituzumab govitecan Trop-2-targeted antibody-drug conjugate in solid tumors and UGT1A1\u221728 polymorphism: a systematic review and meta-analysis","volume":"2","author":"Sultana","year":"2024","journal-title":"BJC Rep"},{"issue":"6","key":"10.1016\/j.cpet.2026.02.003_bib67","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1158\/1535-7163.MCT-24-0254","article-title":"177Lu-labeled antibody-drug conjugate: a dual-mechanistic treatment modality in solid tumors","volume":"24","author":"Yamaguchi","year":"2025","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10.1016\/j.cpet.2026.02.003_bib68","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/s44321-024-00059-5","article-title":"ImmunoPET imaging of Trop2 in patients with solid tumours","volume":"16","author":"Huang","year":"2024","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.1016\/j.cpet.2026.02.003_bib69","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","article-title":"Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"8","author":"Rugo","year":"2022","journal-title":"npj Breast Cancer"},{"issue":"1","key":"10.1016\/j.cpet.2026.02.003_bib70","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1186\/s12951-025-03600-x","article-title":"Rapid diagnostic imaging and targeted immunotoxin delivery in aggressive prostate cancer using CEACAM5-specific nanobodies","volume":"23","author":"Xiao","year":"2025","journal-title":"J Nanobiotechnology"},{"issue":"7","key":"10.1016\/j.cpet.2026.02.003_bib71","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2967\/jnumed.123.267107","article-title":"CEACAM5-targeted immuno-PET in androgen receptor-negative prostate cancer","volume":"65","author":"Imberti","year":"2024","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.cpet.2026.02.003_bib72","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1007\/s00259-025-07321-z","article-title":"Development of a novel anti-CEACAM5 VHH for SPECT imaging and potential cancer therapy applications","volume":"52","author":"Cong","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.cpet.2026.02.003_bib73","first-page":"10","article-title":"Phase I study of yttrium-90 radiolabeled M5A anti-carcinoembryonic antigen humanized antibody in patients with advanced carcinoembryonic antigen producing malignancies","volume":"35","author":"Akhavan","year":"2020","journal-title":"Cancer Biother Radiopharm"},{"issue":"6","key":"10.1016\/j.cpet.2026.02.003_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010929","article-title":"Vicrostatin - an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities","volume":"5","author":"Minea","year":"2010","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.cpet.2026.02.003_bib75","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.toxicon.2011.02.020","article-title":"Development of a chimeric recombinant disintegrin as a cost-effective anti-cancer agent with promising translational potential","volume":"59","author":"Minea","year":"2012","journal-title":"Toxicon"},{"issue":"10\u201312","key":"10.1016\/j.cpet.2026.02.003_bib76","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00726-019-02794-3","article-title":"Preclinical evaluation of a 64Cu-labeled disintegrin for PET imaging of prostate cancer","volume":"51","author":"Jadvar","year":"2019","journal-title":"Amino Acids"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859826000210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859826000210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:40:16Z","timestamp":1780515616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859826000210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1556859826000210"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2026.02.003","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Theranostic Targets for Prostate Cancer Beyond Prostate-Specific Membrane Antigen","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2026.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}